Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

Gottesman, M. M., & PASTAN, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,569

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S. A., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,007

Myelodysplastic Syndromes

Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625

Age and acute myeloid leukemia

Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,371

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

Shallis, R. M., Wang, R., Davidoff, A. J., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 980

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Dinardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., Kadia, T. M., Borthakur, G. M., Ohanian, M. N., Alvarado, Y., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30210-6 · Cited by 324

How I treat acute myeloid leukemia in the era of new drugs

Dinardo, C. D., & Wei, A. H. (2019) · Blood · doi:10.1182/blood.2019001239 · Cited by 293

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Short, N. J., Bravo, G. M., Hwang, H., Ning, J., Franquiz, M. J., Kanagal‐Shamanna, R., Patel, K. P., Dinardo, C. D., Ravandi, F., Garcia‐Manero, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003120 · Cited by 188

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models

Minzel, W., Venkatachalam, A., Fink, A., Hung, E., Brachya, G., Burstain, I., Shaham, M., Rivlin, A., Omer, I., Zinger, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.045 · Cited by 161

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013983 · Cited by 111

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Venugopal, S., Takahashi, K., Daver, N. G., Maiti, A., Borthakur, G. M., Loghavi, S., Short, N. J., Ohanian, M. N., Masárová, L., Issa, G. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00604-2 · Cited by 96

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

Kadia, T. M., Cortes, J. E., Ravandi, F., Jabbour, E. J., Konopleva, M. Y., Benton, C. B., Burger, J. A., Sasaki, K., Borthakur, G. M., Dinardo, C. D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30132-7 · Cited by 96

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Bravo, G. M., Kanagal‐Shamanna, R., Class, C. A., Sasaki, K., Ravandi, F., Cortes, J. E., Daver, N. G., Takahashi, K., Short, N. J., Dinardo, C. D., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25769 · Cited by 68

Trisomy 8 in acute myeloid leukemia

Hemsing, A. L., Hovland, R., Tsykunova, G., & Reikvam, H. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1657400 · Cited by 56

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Short, N. J., Müftüoğlu, M., Ong, F., Nasr, L. F., Macaron, W., Bravo, G. M., Alvarado, Y., Basyal, M., Daver, N. G., Dinardo, C. D., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01476-8 · Cited by 57

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

Ebner, J., Schmoellerl, J., Piontek, M., Manhart, G., Troester, S., Carter, B. Z., Neubauer, H. A., Moriggl, R., Szakács, G., Zuber, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41229-2 · Cited by 50

More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate

Klepin, H. D., Estey, E. H., & Kadia, T. M. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239097 · Cited by 52

Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia

Higgins, A. S., & Shah, M. V. (2020) · Genes · doi:10.3390/genes11070749 · Cited by 51

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

Cheung, E., Perissinotti, A. J., Bixby, D. L., Burke, P. W., Pettit, K. M., Benitez, L. L., Brown, J. M., Scappaticci, G. B., & Marini, B. L. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03606-0 · Cited by 50

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Tsai, C., Tang, J., Tien, F., Kuo, Y., Wu, D.-C., Lin, C., Tseng, M., Peng, Y., Hou, M.-F., Chuang, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003738 · Cited by 49

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

de Leeuw, D. C., Ossenkoppele, G. J., & Janssen, J. J. W. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01299-9 · Cited by 47

The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy

Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 46

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study

Sengsayadeth, S. M., Gatwood, K. S., Boumendil, A., Labopin, M., Finke, J., Ganser, A., Stelljes, M., Ehninger, G., Beelen, D. W., Niederwieser, D. W., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019976 · Cited by 43

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

Boscaro, E., Urbino, I., Catania, F. M., Arrigo, G., Secreto, C., Olivi, M., D’Ardìa, S., Frairia, C., Giai, V., Freilone, R., et al. (2023) · Cancers · doi:10.3390/cancers15133512 · Cited by 42

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

Shouval, R., Fein, J. A., Labopin, M., Cho, C., Bazarbachi, A. A., Baron, F., Bug, G., Ciceri, F., Corbacioglu, S., Galimard, J., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30394-x · Cited by 33

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

Rivera, D., Kim, K., Kanagal‐Shamanna, R., Borthakur, G. M., Bravo, G. M., Daver, N. G., Dinardo, C. D., Short, N. J., Yilmaz, M. E., Pemmaraju, N., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26731 · Cited by 32

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Short, N. J., Venugopal, S., Qiao, W., Kadia, T. M., Ravandi, F., Macaron, W., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Borthakur, G. M., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01229-z · Cited by 31

Secondary Acute Myeloid Leukemia

Winer, E. S. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.003 · Cited by 29

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Huemer, F., Melchardt, T., Jansko, B., Wahida, A., Jilg, S., Jost, P. J., Klieser, E., Steiger, K., Magnes, T., Pleyer, L., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13218 · Cited by 27

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

Reville, P. K., Sasaki, K., Kantarjian, H. M., Daver, N. G., Yilmaz, M. E., Dinardo, C. D., Short, N. J., Borthakur, G. M., Pemmaraju, N., Mehta, R. S., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26451 · Cited by 26

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Short, N. J., Borthakur, G. M., Pemmaraju, N., Dinardo, C. D., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Macaron, W., Ning, J., Ma, J., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2062345 · Cited by 26

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia

Maiti, A., & Konopleva, M. Y. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000567 · Cited by 25

Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst

Shallis, R. M., Weiss, J. J., Deziel, N. C., & Gore, S. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100760 · Cited by 28

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

Kadia, T. M., Ravandi, F., Borthakur, G. M., Konopleva, M. Y., Dinardo, C. D., Daver, N. G., Pemmaraju, N., Kanagal‐Shamanna, R., Wang, X., Huang, X., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26206 · Cited by 24

Clinical Impact of Transformation to Acute Myeloid Leukemia in Patients With Higher-Risk Myelodysplastic Syndromes

Kota, V. K., Ogbonnaya, A., Farrelly, E., Schroader, B. K., Raju, A., Kristo, F., & Dalal, M. R. (2022) · Future Oncology · doi:10.2217/fon-2022-0334 · Cited by 24

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia

Vulaj, V., Perissinotti, A. J., Uebel, J. R., Nachar, V. R., Scappaticci, G. B., Crouch, A., Bixby, D. L., Burke, P. W., Maillard, I. P., Talpaz, M., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.05.011 · Cited by 24

How to address second and therapy‐related acute myelogenous leukaemia

Oliai, C. H., & Schiller, G. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16354 · Cited by 23

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Sweet, K. L., Bhatnagar, B., Döhner, H., Donnellan, W., Frankfurt, O., Heuser, M., Kota, V. K., Liu, H., Raffoux, E., Roboz, G. J., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1950706 · Cited by 23

Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape

Short, N. J., Tallman, M. S., Pollyea, D. A., Ravandi, F., & Kantarjian, H. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00067 · Cited by 22

Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options

Richardson, D. R., Green, S. D., Foster, M. C., & Zeidner, J. F. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00608-6 · Cited by 21

Treatment of Acute Myeloid Leukemia in Older Adults

Alsouqi, A., Geramita, E. M., & Im, A. (2023) · Cancers · doi:10.3390/cancers15225409 · Cited by 23

Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia

Short, N. J., & Kantarjian, H. M. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00167-3 · Cited by 20

Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia

Kamath, G. R., Tremblay, D. A., Coltoff, A. R., Caro, J., Lancman, G., Bhalla, S., Najfeld, V., Mascarenhas, J. O., & Taioli, E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz014 · Cited by 20

The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia

Shallis, R. M., Boddu, P. C., Bewersdorf, J. P., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100639 · Cited by 19

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia

Limongello, R., Marra, A., Mancusi, A., Bonato, S., Hoxha, E., Ruggeri, L., Hui, S. K., Velardi, A., & Pierini, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695051 · Cited by 21

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Senapati, J., Kantarjian, H. M., Haddad, F., Short, N. J., Borthakur, G. M., Kanagal‐Shamanna, R., Tang, G., Jabbour, E. J., Dinardo, C. D., Daver, N. G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27561 · Cited by 17

Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk

Kim, S., Yoon, S., Hong, J., Shin, D., Koh, Y., Byun, J. M., & Kim, I. (2020) · Anticancer Research · doi:10.21873/anticanres.14269 · Cited by 17

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML

Lalayanni, C., Gavriilaki, E., Athanasiadou, A., Iskas, M., Papathanasiou, M., Marvaki, A., Dimou-Mpesikli, S., Papaioannou, G., Mallouri, D., Batsis, I., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.019 · Cited by 17

Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial

Russell, N. H., Hills, R. K., Kjeldsen, L., Dennis, M., & Burnett, A. K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17974 · Cited by 16

Phase II study of cladribine, idarubicin, and ara‐C ( CLIA ) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

Kadia, T. M., Ravandi, F., Molica, M., Bataller, Á., Borthakur, G. M., Daver, N. G., Jabbour, E. J., Dinardo, C. D., Pemmaraju, N., Jain, N., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27054 · Cited by 16

How I treat secondary acute myeloid leukemia

Green, S. D., & Wang, E. S. (2024) · Blood · doi:10.1182/blood.2024024011 · Cited by 20

Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia

Raneros, A. B., Rodríguez, R. M. A., Flórez, A. B., Palomo, P., Colado, E., Minguela, A., Suárez-Álvarez, B., & López‐Larrea, C. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1897294 · Cited by 16

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia

Lee, D. C., Jain, A. G., Deutsch, Y. E., Eatrides, J. M., Chan, O., Padron, E., Kuykendall, A. T., Komrokji, R. S., Lancet, J. E., Sallman, D. A., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.06.001 · Cited by 16

Upregulated mitosis-associated genes CENPE, CENPF, and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia

Shi, M., Guo, H., Bai, Y., Niu, J., Niu, X., Sun, K., & Chen, Y. (2022) · Cancer Biomarkers · doi:10.3233/cbm-203170 · Cited by 15

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia

Ambinder, A. J., & Dezern, A. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033534 · Cited by 16

A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice

Rajagopalan, A., Feng, Y., Gayatri, M. B., Ranheim, E. A., Klungness, T., Matson, D. R., Lee, M. H., Jung, M. M., Zhou, Y., Gao, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci173116 · Cited by 17

Treatment Strategies for Therapy-related Acute Myeloid Leukemia

Dhakal, P., Pyakuryal, B., Pudasainee, P., Rajasurya, V., Gundabolu, K., & Bhatt, V. R. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.007 · Cited by 16

Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China

Dou, X., Dan, C., Zhang, D., Zhou, H., He, R., Zhou, G., Zhu, Y., Fu, N., Niu, B., Xu, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35125 · Cited by 14

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML

Molica, M., Perrone, S., Mazzone, C., Cesini, L., Canichella, M., & de Fabritiis, P. (2022) · Cancers · doi:10.3390/cancers14122843 · Cited by 14

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis

Middeke, J. M., Teipel, R., Röllig, C., Stasik, S., Zebisch, A., Sill, H., Krämer, M., Scholl, S., Hochhaus, A., Jost, E., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864354 · Cited by 13

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy

Jen, W., Sasaki, K., Ravandi, F., Kadia, T. M., Wang, S. A., Wang, W., Loghavi, S., Daver, N. G., Dinardo, C. D., Issa, G. C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013826 · Cited by 12

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials

Ramadan, S. M., Suciu, S., Stevens‐Kroef, M., Willemze, R., Amadori, S., de Witte, T., Löwenberg, B., Muus, P., Labar, B., Meert, L., et al. (2020) · Cancers · doi:10.3390/cancers12113334 · Cited by 12

AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance

Jia, Y., Guo, J., Zhao, Y., Zhang, Z., Shi, L., Fang, Y., Wu, D., Wu, L., & Chang, C. (2021) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmab017 · Cited by 11

Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients

Hecker-Nolting, S., Langer, T., Blattmann, C., Kager, L., & Bielack, S. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287908 · Cited by 10

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Galera, P. K., Dilip, D., Derkach, A., Chan, A. C. L., Zhang, Y., Persaud, S., Mishra, T., Kramer, K., Kathpalia, M., Liu, Y., et al. (2025) · Blood · doi:10.1182/blood.2024026273 · Cited by 11

Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?

Uy, G. L., DeAngelo, D. J., Lozier, J. N., Fisher, D. M., Jonas, B. A., Magnani, J. L., Becker, P. S., Lazarus, H. M., & Winkler, I. G. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101184 · Cited by 10

The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia

Cooperrider, J. H., Shukla, N., Nawas, M. T., & Patel, A. A. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00342 · Cited by 10

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Orvain, C., Arboli, E. R., Othus, M. K. D., Sandmaier, B. M., Deeg, H. J., Appelbaum, F. R., & Walter, R. B. (2023) · Cancers · doi:10.3390/cancers15020352 · Cited by 9

Identification of a prognostic model based on costimulatory molecule-related subtypes and characterization of tumor microenvironment infiltration in acute myeloid leukemia

Mao, Y., Hu, Z., Xu, X., Xu, J., Wu, C., Jiang, F., & Zhou, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.973319 · Cited by 9

Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper

Dennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V. T., Raj, K. K., Thomas, I., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18369 · Cited by 8

Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials

Jammal, N., Rausch, C. R., Kadia, T. M., & Pemmaraju, N. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1847272 · Cited by 8

Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway

Liang, S., Zhou, X., Cai, D., Rodrigues‐Lima, F., Chi, J., & Wang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685954 · Cited by 8

Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia

Parmar, K., Kundu, R., Maiti, A., & Ball, S. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107546 · Cited by 7

Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis

Rinaldi, I., Louisa, M., Wiguna, F., Budiani, E., Mahardhika, J. C., & Hukmi, K. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.10.2827 · Cited by 6

Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt

Sedeta, E. T., Jemal, A., Nisotel, L. E., & Sung, H. (2024) · Cancer · doi:10.1002/cncr.35214 · Cited by 6

Evolution of Therapy for Older Patients With Acute Myeloid Leukemia

Kadia, T. M., & Wei, A. H. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000574 · Cited by 6

Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

Reville, P. K., & Kadia, T. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0710-x · Cited by 6

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

Zhou, X., Mei, C., Zhang, J., Lu, Y., Lan, J., Lin, S., Zhang, Y., Kuang, Y., Ren, Y., Ma, L., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2755 · Cited by 6

Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP / EBMT

Nagler, A., Kayser, S., Ferhat, A. T., Kröger, N. M., Eder, M., Socié, G., Blaise, D., Schroeder, T., Labussière‐Wallet, H., Maertens, J. A., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70164 · Cited by 5

Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?

Roberts, M. D., Langston, A. A., & Heffner, L. T. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00574 · Cited by 5

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities

Boertjes, E. L., Grob, T., Hinai, A. S. A. A., Beverloo, B. H. B., Versluis, J., Kavelaars, F. G., Rijken, M., Compagne, K. G., Erpelinck-Verschueren, C. A. J., Sanders, M. A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018408 · Cited by 6

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

Madrid, P. L., Boluda, B., Martínez‐López, J., Bergua, J., Arboli, E. R., Labrador, J., Sossa, C., Gil, C., Algarra, L., Lavilla, E., et al. (2025) · Cancer · doi:10.1002/cncr.35696 · Cited by 4

Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms

Jahn, J., Diamond, B. T., Hsu, J., Montoya, S., Totiger, T. M., Landgren, O., Maura, F., & Taylor, J. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107020 · Cited by 3

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Kayser, S., Nagler, A., Ferhat, A.-T. L. S., Sanz, J., Blaise, D., Koç, Y., Raiola, A. M., Busca, A., Kulagin, A., Vydra, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02951-9 · Cited by 3

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience

Karasek, M., Armatys, A., Skarupski, M., Bołkuń, Ł., Budziszewska, B. K., Drozd-Sokolowska, J. E., Zarzycka, E., Mensah‐Glanowska, P., Gajewska, M., Hałka, J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1395992 · Cited by 3

Behandling av akutt myelogen leukemi hos eldre

Reikvam, H., Dalgaard, J., Johansen, S., Tvedt, T. H. A., & Bruserud, Ø. (2019) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.18.0775 · Cited by 3

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review

Cortes, J. E., Candoni, A., Clark, R. E., Leber, B. F., Montesinos, P., Vyas, P., Zeidan, A. M., & Heuser, M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1817445 · Cited by 3

Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

Asghari, H. H., & Lancet, J. E. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1719093 · Cited by 3

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities

Hassanein, M. F. R., Fakih, R. O. E., Rasheed, W. K., Ahmed, S. O., Shaheen, M., Chaudhri, N. A., Alsharif, F. Z., Ahmed, S., Hanbali, A. S., Alshaibani, A., et al. (2021) · eJHaem · doi:10.1002/jha2.136 · Cited by 3

Acute myeloid leukemia with mixed phenotype is characterized by RUNX1 mutations, stemness features and limited lineage plasticityPreprint

Galera, P. K., Dilip, D., Derkach, A., Chan, A. C. L., Zhang, Y., Persuad, S., Mishera, T., Liu, Y., Famulare, C. A., Gao, Q., et al. (2023) · medRxiv · doi:10.1101/2023.11.01.23297696 · Cited by 3

A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia

Jen, W., Croden, J., Almanza, E., Dinardo, C. D., Chien, K. S., Hammond, D. E., Qiao, W., Alvarado, Y., Masárová, L., Quesada, A. E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70214 · Cited by 2

Consenso de leucemia mieloide aguda en México

Arana-Luna, L. L., Alvarado‐Ibarra, M., Silva-Michel, L. G., Morales-Maravilla, A., González-Rubio, M. D. C., Chavez-Aguilar, L. A., Tena-Iturralde, M. F., Mojica-Balderas, L., Zapata-Canto, N. P., Galindo-Delgado, P., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000597 · Cited by 2

AHR signaling pathway mediates mitochondrial oxidative phosphorylation which leads to cytarabine resistance

Jia, Y., Li, X., Chen, L., Li, L., Zhang, S., Huang, W., & Zhang, H. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024022 · Cited by 2

Characteristics and Survival of Secondary Acute Myeloid Leukemia From Myelodysplastic Syndromes in Older Adults: A Population Analysis

Batra, A., Sparks, A. D., Singh, R., Zakai, N. A., & Herrera, D. A. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.012 · Cited by 2

Molecular insights and treatment innovations: Advancing outcomes in acute myeloid leukemia with myelodysplasia‑related changes (Review)

Qiu, H., Zhang, C., Ma, X., & Li, Y. (2025) · Oncology Reports · doi:10.3892/or.2025.8887 · Cited by 2

Efficacy of Azacitidine Plus Venetoclax in Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome after Failure of Azacitidine Monotherapy

Furumoto, T., Ando, K., Toriyama, E., Hata, T., Katsuoka, S., Nishimura, S., Ichinose, M., Hashimoto, M., Fujioka, M., Sakaki, C., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5312-25 · Cited by 2

Pediatric Germline Predisposition to Myeloid Neoplasms

Thompson, C., Ariagno, S. N., & Kohorst, M. A. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00681-5 · Cited by 2

Consensus in acute myeloid leukemia in Mexico

Arana-Luna, L. L., Alvarado‐Ibarra, M., Silva-Michel, L. G., Morales-Maravilla, A., González-Rubio, M. D. C., Chávez-Aguilar, L. A., Tena-Iturralde, M. F., Mojica-Balceras, L., Zapata-Canto, N., Galindo-Delgado, P., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000598 · Cited by 2

Allogeneic stem cell transplantation remains an effective therapeutic approach for patients with therapy-related acute myeloid leukemia

Spałek, A. M., Woźniczka, K., Armatys, A., Matlak, K., Koclęga, A., Kata, D., Wieczorkiewicz-Kabut, A., & Helbig, G. (2021) · Acta Haematologica Polonica · doi:10.5603/ahp.2021.0016 · Cited by 2

Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351

Makishima, H., Mikasa, T., Isogaya, K., Miyamoto, T., Yamauchi, T., Yokota, A., Onozawa, M., Ando, K., Ogawa, Y., Usuki, K., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03956-8 · Cited by 1

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Swaminathan, M., Dinardo, C. D., Maiti, A., Pemmaraju, N., Ohanian, M. N., Daver, N. G., Garcia‐Manero, G., Issa, G. C., Borthakur, G. M., Ravandi, F., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01265-1 · Cited by 1

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation

Kashima, E., Sugimoto, Y., Nagaharu, K., Ohya, E., Ikejiri, M., Watanabe, Y., Kageyama, S., Oka, K., & Tawara, I. (2024) · Hematology · doi:10.1080/16078454.2024.2392908 · Cited by 1

Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients

Kamath, G. R., Tremblay, D. A., Coltoff, A. R., Caro, J., Lancman, G., Bhalla, S., Najfeld, V., Mascarenhas, J. O., & Taioli, E. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.12.006 · Cited by 1

Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes

Matsukawa, T., Yoshida, S. Y., Onozawa, M., Fujii, F., Nagai, J., Takahashi, T., Ota, S., Hashiguchi, J., Mori, A., Miyagishima, T., et al. (2026) · Figshare · doi:10.6084/m9.figshare.31310112

Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification

Afrough, A., Talukder, R., Yellapragada, S. V., Teegavarapu, P. S., Mims, M. P., & Rivero, G. (2019) · Blood · doi:10.1182/blood-2019-129183

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML

Lalayanni, C., Gavriilaki, E., Athanasiadou, A., Iskas, M., Papathanasiou, M., Marvaki, A., Dimou-Mpesikli, S., Papaioannou, G., Mallouri, D., Batsis, I., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.019 · Cited by 17

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Senapati, J., Kantarjian, H. M., Haddad, F., Short, N. J., Borthakur, G. M., Kanagal‐Shamanna, R., Tang, G., Jabbour, E. J., Dinardo, C. D., Daver, N. G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27561 · Cited by 17

Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk

Kim, S., Yoon, S., Hong, J., Shin, D., Koh, Y., Byun, J. M., & Kim, I. (2020) · Anticancer Research · doi:10.21873/anticanres.14269 · Cited by 17